Acelyrin Inc. (SLRN)
2.47
-0.13 (-5.00%)
At close: Mar 31, 2025, 3:59 PM
2.49
1.00%
After-hours: Mar 31, 2025, 05:24 PM EDT
-5.00% (1D)
| Bid | 2.36 |
| Market Cap | 248.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -251.75M |
| EPS (ttm) | -2.5 |
| PE Ratio (ttm) | -0.99 |
| Forward PE | -0.86 |
| Analyst | Hold |
| Ask | 2.6 |
| Volume | 1,482,446 |
| Avg. Volume (20D) | 2,232,115 |
| Open | 2.52 |
| Previous Close | 2.60 |
| Day's Range | 2.44 - 2.54 |
| 52-Week Range | 1.84 - 7.25 |
| Beta | 1.29 |
About SLRN
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials...
Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2023
Employees 83
Stock Exchange NASDAQ
Ticker Symbol SLRN
Website https://www.acelyrin.com
Analyst Forecast
According to 5 analyst ratings, the average rating for SLRN stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 142.91% from the latest price.
Stock Forecasts1 month ago
+19.82%
ACELYRIN shares are trading higher after the compa...
Unlock content with
Pro Subscription
2 months ago
-36.96%
Acelyrin shares are trading lower after HC Wainwright & Co. cut its price target on the stock from $8 to $6.
